Evidence map›Paper›PMID 40508215›Full record

ArticleInternational journal of molecular sciences2025

Life-Threatening Macrophage Activation Syndrome in Pregnancy: First Manifestation of SLE Induced by Parvovirus B19.

Aleksandra Plavsic, Rada Miskovic, Dragana Jovanovic, Uros Karic, Zikica Jovicic, Sara Radovic, Ana Drazic, Aleksandra Dasic, Snezana Arandjelovic

Abstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Human parvovirus B19 infection in a Spanish healthcare area: epidemiology, clinical spectrum, and factors associated with hospitalization.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aleksandra PlavsicClinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
Rada MiskovicClinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0003-0982-2572
Dragana JovanovicClinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
Uros KaricFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Zikica JovicicClinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-8805-8391
Sara RadovicClinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
Ana DrazicClinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
Aleksandra DasicClinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.ORCID 0009-0001-0155-4588
Snezana ArandjelovicClinic for Allergy and Immunology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophage activation syndrome (MAS) is a complex, life-threatening, hyperinflammatory condition occurring as a form of hemophagocytic lymphohistiocytosis (HLH), commonly associated with several autoimmune and autoinflammatory diseases, and certain infections such as Parvovirus B19 (P19V). The onset of systemic lupus erythematosus (SLE) presenting as MAS during pregnancy is uncommon, posing significant diagnostic and therapeutic challenges. We present a case of a 30-year-old woman at the 12th gestational week with fever, arthralgia, rash, cervical lymphadenopathy, cytopenia, and elevated liver enzyme. Bone marrow biopsy revealing hemophagocytosis, elevated ferritin and triglycerides, high interleukin-2, fever and cytopenia, confirmed the diagnosis of HLH. Further evaluation revealed the diagnosis of SLE. Treatment was initiated with intravenous immunoglobulin and corticosteroids. Given the deterioration in the patient's clinical condition, a decision was made to terminate the pregnancy. She continued in the following months to receive SLE treatment with corticosteroids, cyclophosphamide, hydroxychloroquine, and later with mycophenolate mofetil due to the development of Class IV of lupus nephritis. P19V IgM antibodies were initially positive, later seroconverted to IgG, indicating that infection may have acted as a trigger for the onset of SLE and MAS development during pregnancy. The overlapping clinical features of P19V infection, SLE, and MAS pose significant diagnostic and therapeutic challenges. Early recognition and comprehensive diagnostic evaluation are crucial for the management of these conditions, especially during pregnancy, where both maternal outcomes are at risk.

Indexed as

Lupus Erythematosus, SystemicMacrophage Activation SyndromeParvoviridae InfectionsParvovirus B19, HumanPregnancy Complications, InfectiousAdrenal Cortex HormonesAdultFemaleHumansLymphohistiocytosis, HemophagocyticPregnancyAdrenal Cortex Hormoneshemophagocytic lymphohistiocytosis (HLH)parvovirus B19 (P19V)P (MAS)pregnancysystemic lupus erythematosus (SLE)

Identifiers

PMID40508215
PMCPMC12155505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.